CDC Releases National Human Exposure Data on 27 Pollutants

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 6
Volume 10
Issue 6

WASHINGTON-National exposure data for 27 contaminants are detailed in the first National Report on Human Exposure to Environmental Chemicals, assembled and released by the Centers for Disease Control and Prevention (CDC). Unlike studies that estimate population exposures by measuring air, water, and soil samples, the new data represent direct measurements of chemicals in blood and urine samples. The samples were collected in 1999 as part of CDC’s periodic National Health and Nutrition Examination Survey.

WASHINGTON—National exposure data for 27 contaminants are detailed in the first National Report on Human Exposure to Environmental Chemicals, assembled and released by the Centers for Disease Control and Prevention (CDC). Unlike studies that estimate population exposures by measuring air, water, and soil samples, the new data represent direct measurements of chemicals in blood and urine samples. The samples were collected in 1999 as part of CDC’s periodic National Health and Nutrition Examination Survey.

CDC had previously assessed the population exposure of only three of the substances listed in the new report—lead, cadmium, and cotinine. Cotinine, a byproduct of the breakdown of nicotine after it enters the body, serves as a marker for a person’s exposure to tobacco smoke, either primary or secondary.

The report showed a 75% decrease in serum cotinine levels of nonsmokers in the United States, documenting "a dramatic reduction in exposure of the US population to environmental tobacco smoke since 1991," said Richard Jackson, MD, director of CDC’s National Center for Environmental Health.

Other metals covered in the report include mercury, cobalt, antimony, barium, beryllium, cesium, molybdenum, platinum, thallium, tungsten, and uranium. The pesticide data include six metabolites of organophosphate pesticides, which represent exposure to 28 pesticides. Also included are data on seven phthalate metabolites, found in many plastics.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.